Stocks · News reference

Femasys Secures FDA Pathway for Non-Surgical Contraceptive

Aug 19, 2026, 5:36 PMVandana Singh

FDA clears modular PMA pathway for Femasys' FemBloc, an investigational non-surgical permanent birth control device for women in the US.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 19, 2026, 5:36 PM
Checked: Aug 19, 2026, 5:36 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 26, 2026, 1:04 PMBenzinga Newsdesk
Femasys Partners With UNC Health To Introduce Fertility Diagnostics, FemVue And SpermVue, Together With Femaseed Complete Within UNC Health OB/GYN Practice Locations
-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fertility evaluation and FemaSeed as a first-line treatment option --ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys
Read original at benzinga
FEMY
BenzingaAug 19, 2026, 2:29 PMBenzinga Newsdesk
Femasys shares are trading higher after the company announced that the U.S. Food and Drug Administration has approved the company’s modular premarket approval application pathway for FemBloc.
Read original at benzinga
FEMY
BenzingaAug 19, 2026, 1:01 PMBenzinga Newsdesk
Femasys Says FDA Approved Modular PMA Pathway For FemBloc Non-Surgical Permanent Birth Control
Read original at benzinga
FEMY